Berkestedt Ingrid, Andersson Pia, Herwald Heiko, Valik John Karlsson, Sörensen Ola, Bodelsson Mikael
Department of Clinical Sciences Lund, Anaesthesiology and Intensive Care, Lund University, Skane University Hospital, Lund, Sweden.
Department ofInfection Medicine, Lund University, Skane University Hospital, Lund, Sweden.
APMIS. 2018 Dec;126(12):892-898. doi: 10.1111/apm.12898. Epub 2018 Nov 5.
Activation of the contact system generates bradykinin from high-molecular-weight kininogen and has been suggested to participate in the pathophysiology of sepsis. To test this, we prospectively measured bradykinin and high-molecular-weight kininogen levels in a cohort of sepsis patients requiring intensive care. From 29 patients meeting criteria for sepsis or septic shock according to Sepsis-3, blood was sampled within 24 h and on the fourth day following admittance to intensive care. Patients planned for neurosurgery served as matched controls. Sequential organ failure assessment score and 90-day mortality was registered. Bradykinin levels (median [interquartile range]) were lower in sepsis patients (79 [62-172] pg/ml) compared to controls (130 [86-255] pg/ml, p < 0.025) and did not correlate with mortality or severity of circulatory derangement. High-molecular-weight kininogen levels were lower in sepsis patients (1.6 [0.8-4.8] densitometry units) compared to controls (4.4 [2.9-7.7] densitometry units, p < 0.001), suggesting previous contact system activation. High-molecular-weight kininogen levels were lower in non-survivors than survivors (p = 0.003) and negatively correlated to severity of circulatory derangement. We conclude that a role for bradykinin in later stages of severe sepsis must be challenged. Low high-molecular-weight kininogen concentrations suggest that the decrease in bradykinin is due to substrate depletion.
接触系统的激活可从高分子量激肽原生成缓激肽,有人认为其参与了脓毒症的病理生理过程。为验证这一点,我们前瞻性地测定了一组需要重症监护的脓毒症患者体内缓激肽和高分子量激肽原的水平。根据脓毒症-3标准,从29例符合脓毒症或脓毒性休克标准的患者中,在进入重症监护病房后的24小时内及第四天采集血液样本。计划进行神经外科手术的患者作为匹配对照。记录序贯器官衰竭评估评分和90天死亡率。与对照组(130 [86 - 255] pg/ml,p < 0.025)相比,脓毒症患者的缓激肽水平(中位数[四分位间距])较低(79 [62 - 172] pg/ml),且与死亡率或循环紊乱的严重程度无关。与对照组(4.4 [2.9 - 7.7] 光密度测量单位,p < 0.001)相比,脓毒症患者的高分子量激肽原水平较低(1.6 [0.8 - 4.8] 光密度测量单位),提示先前接触系统已被激活。非存活者的高分子量激肽原水平低于存活者(p = 0.003),且与循环紊乱的严重程度呈负相关。我们得出结论,必须对缓激肽在严重脓毒症后期所起的作用提出质疑。高分子量激肽原浓度较低表明缓激肽的减少是由于底物耗竭。